Back to companies

Bavarian Nordic AS (Bavarian Nordic) is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, respiratory syncytial virus, COVID-19, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.

Headquarters Denmark

Address Philip Heymans Alle 3, Hellerup, 2900


No of Employees 868

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange BAVA (CPH)

Revenue (2021) $301.8M 2.5% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -267.5% (2021 vs 2020)

Market Cap* $2.3B

Net Profit Margin (2021) XXX -263.5% (2021 vs 2020)

   

* As of and is in US$

Access premium data and analytics for Bavarian Nordic AS

80+

Clinical Trials

Determine Bavarian Nordic AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Catalyst Calendar

Proactively evaluate Bavarian Nordic AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Bavarian Nordic AS’s relevant decision makers and contact details.

20+

Pipeline Drugs

Identify which of Bavarian Nordic AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

13+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

6

Marketed Drugs

Understand Bavarian Nordic AS’s commercialized product portfolio to stay one step ahead of the market.

5

Sales & Consensus Forecasts

Understand the current and future drug revenue for Bavarian Nordic AS and assess market opportunity for new entrants with patient population 8-year forecasts.

14+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Bavarian Nordic AS’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Jynneos/Imavanex- Smallpox and Monkeypox Vaccine Jynneos
Rabipur/Rabavert- Rabies Vaccine Imvanex
Encepur- Tick-Borne Encephalitis Vaccine Imvamune
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In September, the company announced the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
2022 Contracts/Agreements In September, the company entered into a partnership with the European Health Emergency Preparedness and Response Authority for an additional 170,000 doses of MVA-BN smallpox/monkeypox vaccine.
2022 Regulatory Approval In July, the company secured approval from European Commission for its Imvanex vaccine to be marketed as protection against monkeypox.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Bavarian Nordic AS BioNTech SE Moderna Inc Novavax Inc Icosavax Inc
Headquarters Denmark Germany United States of America United States of America United States of America
City Hellerup Mainz Cambridge Gaithersburg Seattle
State/Province - - Massachusetts Maryland Washington
No. of Employees 868 3,082 2,700 1,541 34
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Gerard Van Odijk, M.D. Chairman Executive Board 2014 65
Paul Chaplin President; Chief Executive Officer Senior Management 2014 55
Henrik Juuel Chief Financial Officer; Executive Vice President Senior Management 2018 57
Russell Thirsk Chief Operating Officer; Executive Vice President Senior Management 2022 54
Anu Helena Kerns Executive Vice President; Chief People Officer Senior Management 2020 50
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?